Date: 2016-06-06
Type of information: Collaboration agreement
Compound: large-scale microbial-biologics facility
Company: Fujifilm Diosynth Biotechnologies (USA - NC) Merck&Co (USA - NJ)
Therapeutic area: Technology - Services
Type agreement: collaboration production manufacturing
Action mechanism:
Disease:
Details: * On June 6, 2016, Fujifilm Diosynth Biotechnologies announced that it is in the process of establishing a long-term collaboration with Merck&Co to invest in and operate a new 20,000-Liter microbial-biologics facility for supply of active pharmaceutical ingredient to its customers. This collaboration involves a $60-million investment by Merck&Co at its Brinny manufacturing plant in Innishannon, County Cork, Ireland. This plant is an integrated site for the development, testing and manufacturing of biologics. It is intended that the large-scale biologics operations at Merck&Co in Brinny will be operational in early 2018 for biotech and pharma customers of Fujifilm Diosynth. Merck&co facility in Brinny will operate as cGMP manufacturing support for Fujifilm Diosynth’s CDMO business, enabling seamless technology transfer and technical support. These new capacities will complement Fujifilm Diosynth’s existing microbial capacity that ranges from 100L up to 5000L both in the USA and UK.
Financial terms:
Latest news:
